Heart Failure
Aortic Insufficiency and Right Heart Failure After Preoperative Microaxial Flow Device Support — Intermacs Analysis
- Authors: STS Intermacs investigators
- Journal / date: J Heart Lung Transplant, 2026
- DOI / URL: 10.1016/j.healun.2026.05.011 | PMID 42176716
- Source basis: Abstract only
- Study type: Registry analysis (STS Intermacs), Cox multivariable + propensity-matched
- Population:
- AI analysis: 5942 adults receiving fully magnetically levitated centrifugal dLVAD (HeartMate 3), Nov 2020-Dec 2024
- 32.6% no tMCS, 33.3% IABP, 27.4% microaxial flow pump (mAFP, Impella), 6.7% VA-ECMO pre-implant
- Primary findings:
- Moderate or worse AI at 24 months: mAFP HR 1.79 (1.43-2.24) adjusted; PS-matched 21.4% vs 15.3% (HR 1.75, 1.29-2.38) vs no tMCS
- RHF within 24 months: 20.1% overall; mAFP adjusted HR 1.34 (1.16-1.55); PS-matched HR 1.20 (0.97-1.49), trend
- Why it matters (clinical takeaway):
- Preoperative Impella support nearly doubles the risk of post-LVAD aortic insufficiency and confers a meaningful RHF signal — both are leading drivers of late LVAD morbidity/mortality.
- Reinforces the need to evaluate AV apparatus integrity and existing AI carefully before and after mAFP bridge.
- Practical: shock teams and LVAD selection committees should weight pre-implant mAFP exposure as an additional risk modifier, and may favor strategies (e.g., IABP-first when feasible, earlier transition to durable support) that limit mAFP duration.
- Caveats / limitations: Observational, registry. Channels for selection bias (sicker patients get mAFP). Mechanism (valve apparatus damage vs masking of AI at implant) not directly tested.
- Referenced trials pulled forward: DanGer Shock (AMI-CS context for Impella benefit) — to add to trials/ on next pass.